Viel A, Dall'Agnese L, Canzonieri V, Sopracordevole F, Capozzi E, Carbone A, Visentin M C, Boiocchi M
Division of Experimental Oncology I, Centro di Riferimento Oncologico, Aviano, Italy.
Cancer Res. 1995 Jun 15;55(12):2645-50.
The nm23-H1 gene has been proposed as a metastasis suppressor gene. It is located on the long arm of chromosome 17, which is frequently deleted in ovarian cancer, and shows altered expression and structure in some advanced neoplasms. To evaluate the role of nm23-H1 in ovarian carcinogenesis, we have analyzed this gene in 66 primary human ovarian carcinomas at both the DNA and RNA levels. Despite the high frequency (76%) of nm23-H1 loss of heterozygosity (LOH), the complete absence of gene mutations in the coding portions of the retained allele clearly indicated that, in ovarian carcinomas, this gene does not function in the same way as do classic oncosuppressor genes. The relationship of clinicopathological parameters with nm23-H1 gene deletions and expression levels was also investigated. LOHs were more common in the serous and endometrioid histotypes (85 and 93%, respectively), and the highest LOH frequency was detected in poorly differentiated tumors (89%). A significant relationship between nm23-H1 mRNA expression and lymph node metastasis was observed in high-grade tumors, which are intrinsically more invasive than are low-grade tumors. In particular, among the poorly differentiated tumors showing areas of undifferentiated solid carcinoma (classified as G3/G4), lymph node-negative tumors displayed expression levels that were significantly higher than those of lymph node-positive tumors (P < 0.001). In conclusion, our data suggest that the nm23-H1 gene product may exert an inhibitory effect on the lymphatic dissemination of human ovarian tumors. However, several other factors, biological or time and patient dependent, influence the complex metastatic progression of ovarian tumors and may cooperate with nm23-H1 in the promotion or inhibition of this process.
nm23-H1基因被认为是一种转移抑制基因。它位于17号染色体长臂上,在卵巢癌中该区域常发生缺失,并且在一些晚期肿瘤中其表达和结构会发生改变。为了评估nm23-H1在卵巢癌发生中的作用,我们在DNA和RNA水平上对66例原发性人类卵巢癌中的该基因进行了分析。尽管nm23-H1杂合性缺失(LOH)的频率很高(76%),但保留等位基因编码部分完全没有基因突变,这清楚地表明,在卵巢癌中,该基因的功能与经典的抑癌基因不同。我们还研究了临床病理参数与nm23-H1基因缺失及表达水平之间的关系。LOH在浆液性和子宫内膜样组织学类型中更为常见(分别为85%和93%),在低分化肿瘤中检测到的LOH频率最高(89%)。在高级别肿瘤中观察到nm23-H1 mRNA表达与淋巴结转移之间存在显著关系,高级别肿瘤本质上比低级别肿瘤更具侵袭性。特别是,在显示未分化实体癌区域的低分化肿瘤(分类为G3/G4)中,淋巴结阴性肿瘤的表达水平显著高于淋巴结阳性肿瘤(P < 0.001)。总之,我们的数据表明nm23-H1基因产物可能对人类卵巢肿瘤的淋巴扩散发挥抑制作用。然而,其他几个因素,无论是生物学因素还是与时间和患者相关的因素,都会影响卵巢肿瘤复杂的转移进程,并且可能与nm23-H1协同促进或抑制这一过程。